Source | Groups | Baseline | Treatment endpoint | Change after treatment | P value (Intervention vs Placebo) | Significant Difference |
---|---|---|---|---|---|---|
Sputum eosinophils (10 6 /g) | ||||||
Singh 2013 [13] | Intervention | NM | 0.4## | NM | 0.002 | Yes |
Control | NM | 0.75## | NM | |||
Kuna (trial 1) 2016 [21] | Intervention | 0.024 (0.00 to 0.53)§ | 0.004 (0.00 to 0.53)§ | NM | NM | No |
Control | 0.033 (0.00 to 1.21)§ | 0.014 (0.00 to 0.73)§ | NM | |||
Sputum eosinophils (%) | ||||||
Barnes 2012 [11] | Intervention | 2.1 (NM)‡ | 0.7 (NM)‡ | 3.1 (1.1, 8.8)§§ | 0.37 | No |
Control | 1.8(NM)‡ | 1.2 (NM)‡ | 1.5 (0.4, 5.3)§§ | |||
Singh 2013 [13] | Intervention | 6.0 (1.5, 23.9)‡ | 18.1 (10.0, 33.2)‡ | NM | 0.002 | Yes |
Control | 6.0 (1.5, 23.9)‡ | 5.6 (2.7, 11.6)‡ | ||||
Busse 2013 [17] | Intervention | 2.0 (0 to 93)§ | NM | −3.5 (−93 to 5)§ | NM | No |
1.0 (0 to 69)§ | NM | −0.5 (−68 to 36)§ | NM | |||
1.0 (0 to 91)§ | NM | 0.0 (−72 to 6)§ | NM | |||
1.0 (0 to 80)§ | NM | 0.0 (−24 to 4)§ | NM | |||
Control | 0.0 (0 to 53)§ | NM | 2.0 (−2.3 to 84)§ | – | ||
Gonem 2016 [20] | Intervention | 5.4 (3.1, 9.6)‡ | 1.1 (0.7, 1.9)‡ | 0.22 (0.13, 0.39)§§ | 0.0014 | Yes |
Control | 4.6 (2.5–8.7)‡ | 3.9 (2.3–6.7)‡ | 0.78 (0.45, 1.33)§§ | |||
Blood eosinophils (10 9 /L) | ||||||
Gonem 2016 [20] | Intervention | 0.29 (95.03)# | 0.29 (0.23–0.36)‡ | 1.01 (0.79, 1.28)§§ | 0.44 | No |
Control | 0.28 (80.63)# | 0.32 (0.25, 0.41)‡ | 1.13 (0.89, 1.43)§§ | |||
Kuna (trial 1) 2016 [21] | Intervention | NM | NM | NM | NM | No |
Control | NM | NM | NM | |||
Diamant 2014 [24] | Intervention | NM | NM | NM | NM | No |
Control | NM | NM | NM | |||
FeNO (ppb) | ||||||
Singh 2013 [13] | Intervention | 33.9 (22.4)* | 26.3 (23.7)* | NM | NM | No |
Control | 39.3 (23.9)* | 23.3 (22.8)* | NM | |||
Bateman 2017 [16] | Intervention | NM | NM | NM | > 0.05 | No |
NM | NM | NM | > 0.05 | |||
NM | NM | NM | > 0.05 | |||
Control | NM | NM | NM | – | ||
Busse 2013 [17] | Intervention | 31.9 (21.4)* | NM | 0.221 | > 0.05 | No |
30.9 (30.5)* | NM | 2.368 | > 0.05 | |||
28.3 (23.2)* | NM | −0.080 | > 0.05 | |||
33.5 (31.6)* | NM | 1.333 | > 0.05 | |||
Control | 28.1 (22.0)* | NM | −7.000 | – | ||
Gonem 2016 [20] | Intervention | 37.72 (4.75)†| 34.88 (3.97)†| −5.82 (−13.79, 2.16)** | 0.49 | No |
Control | 43.67 (6.97)†| 38.48 (4.32)†| −2.21 (−10.90, 6.48)** | |||
Kuna (trial 1) 2016 [21] | Intervention | NM | NM | NM | NM | No |
Control | NM | NM | NM | |||
Diamant 2014 [24] | Intervention | 51.6 (38.5)* | NM | NM | NM | No |
Control | 71.0 (36.5)* | NM | NM | |||
Methacholine PC 20 (mg/mL) | ||||||
Singh 2013 [13] | Intervention | 1.48 (3.2)* | 0.31* | NM | NM | No |
Control | 1.48 (3.2)* | 0.39* | ||||
Diamant 2014 [24] | Intervention | 0.91 (2.21)††| 0.97 (1.98)††| NM | 0.038 | Yes |
Control | 1.00 (2.19)††| 0.49 (2.19)††|